Objective: The aim of this study was to explore whether low dose Glycididazolum natrium (CMNa) used during intervention for advanced non-small cell lung cancer (NSCLC) patients can enhance chemo-sensitivity and to evaluate its clinical value. Methods: One hundred and twenty cases of advanced NSCLC patients treated by intervention chemotherapy through bronchial artery, collected from 2005 to 2008, were randomly divided into two groups: experimental group (group A), 75 cases, 0.25g CMNa was administered before chemical drugs; control group (group B), 45 cases, chemical drugs only. There were no differences of operation procedures and chemo-regimens between the two groups. After intervention, imaging and clinical data were collected periodically and were processed statistically. Results: The effective rate of group A was higher than that of group B (P < 0.05). Responsive rate (RR) in group A was 61% and it was 38% in group B. There were some side effects in the two groups but there were no statistical differences. Conclusion: Low dose CMNa can enhance chemosensitivity during intervention, which can elevate chemotherapeutical effects on NSCLC. Meanwhile the side effects were not increased. This method is worthy of popularizing.
展开▼
